Fehmi Keçe

Advances in Atrial Fibrillation Ablation Devices 33 2 Table 1a. Continued. Author, year (study type) Number of patients and type of ablation device PAF (%) Preventive techniques AAD free survival (1 year) (%) Procedural and ablation time (min) Complications (%) Luik, 2015 (161) (RCT) N=159 RF 100 N.A 60 174 (IQR 147- 218) N.A. - Pericardial effusion 1.9 - Vascular access 3.1 Mugnai, 2014 (88) (retrospective) N=260 RF 100 Power reduction (35W anterior and 25W posterior); Temperature limit 48˚C 63 192 (P<0.001) N.A. 36 - Pericardial effusion/Cardiac tamponade 10/1.5 - Vascular access 0.8 - Other: Third degree AV-block/Sinus arrest 0.8; Contrast reaction 0.4 Providencia, 2017 (162) (multicenter retrospective) N=467 RF 100 Power reduction (30W anterior and 25W posterior) 46–79 at 18m 136 (p=0.001) N.A. - Pericardial effusion 1.7 (p=0.036) - TIA 0.2 - Oesophageal bleeding 0.2 - Vascular access 1.9 - Other 0.9 (haemoptysis, haematuria, anaphylactic shock and temporary myocardial sideration) Schmidt, 2014 (90) (multicenter retrospective) N=2870 RF 100 Centers preference N.A. 165 (IQR 120- 210) 33 (IQR 21-50) (P<0.001) - Cardiac tamponade 1.4 - Phrenic nerve palsy 0.0 (p=0.001) - Vascular access 1.1 and 1.1 - Other: pneumothorax 0.3, hemothorax 0.2 ; sepsis 0.0 and surgical accident 0.1 Squara, 2015 (91) (multicenter retrospective) n=178 RFA 100 Power reduction (30- 35W anterior and 20 W posterior) Oesophageal monitoring (discretion of the operator 38.5C cut-off) 83 DC testing 123 (p=0.003) N.A. - Cardiac tamponade 1 - Embolic events 1 - Oesophageal complication 0.5 - Vascular access 4